Insulin by Jet-injection for Hyperglycemia in Diabetes
Launched by UNIVERSITY MEDICAL CENTER NIJMEGEN · Sep 17, 2013
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Recently, we showed in both healthy, non-diabetic volunteers and in patients with type 1 (T1DM) and insulin-treated type 2 diabetes (T2DM) a 40-50% faster absorption of rapid-acting insulin analogues when administered by jet injection technology rather than by conventional insulin pen. The faster insulin action of insulin administration by jet injection may be especially advantageous for correction of hyperglycemia.
To investigate this, a open-label randomised controlled cross-over study will be performed in 20 adult patients (18-75 years) with T1DM or T2DM on basal-bolus insulin treatment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diabetes mellitus type 1 or 2
- • Age 18-75 years
- • Body-Mass Index ≥25 kg/m2 and ≤40 kg/m2
- • Stable glycaemic control with HbA1c ≥48 (6.5%) and ≤86 mmol/mol (10%)
- • Insulin treatment according to basal-bolus regimen, i.e. by multiple daily injections at least four times daily, or by subcutaneous insulin pump, for at least 12 months, use of metformin allowed
- Exclusion Criteria:
- • Inability to provide informed consent
- • Insulin requirement of \<34 or \>200 units per day
- • Treatment with systemic corticosteroids, immunosuppressive or cytostatic drugs
- • Known allergy to aspart insulin
- • Use of oral antidiabetic drugs other than metformin
- • Symptomatic diabetic neuropathy
- • History of a major cardiovascular disease event (myocardial infarction, stroke, symptomatic peripheral artery disease, coronary bypass surgery, percutaneous coronary or peripheral artery angioplasty) in the previous 6 months
- • Pregnancy or the intention to become pregnant
- • Renal disease (creatinine \>150 μmol/l or MDRD-GFR \<30 ml/min/1.73m2)
- • Liver disease (aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range)
- • Presence of any other medical condition that might interfere with the study protocol
- • anemia
About University Medical Center Nijmegen
University Medical Center Nijmegen (UMC Nijmegen) is a leading academic medical center located in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and advanced medical education. As a key player in clinical trials, UMC Nijmegen leverages its multidisciplinary expertise and state-of-the-art facilities to conduct pioneering studies that aim to enhance treatment options and improve health outcomes. The center collaborates with various national and international partners to foster translational research, ensuring that scientific advancements are effectively integrated into clinical practice. With a strong focus on ethical standards and patient safety, UMC Nijmegen is dedicated to contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, , Netherlands
Nijmegen, , Netherlands
Patients applied
Trial Officials
Bastiaan de Galan, MD PhD
Study Chair
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials